Evaluating human induced pluripotent stem cell-derived cardiomyocytes for commercial drug testing
Publication Date
July 24, 2020
Creator
Abstract
The cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high attrition rate in clinical development caused by cardiotoxicity. Since the recent discovery of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs), it has been developed as a novel, promising in vitro research tool in preclinical testing of drug-induced cardiotoxicity. However, major limitation of currently available hiPSC-CMs is their immature phenotype, which can hinder evaluation of contractile dysfunction.
Existing contractility monitoring on hiPSC-CMs is currently being done at low throughput or by using surrogate markers (e.g. impedance). In addition, there has been no detailed cross-site validation study to evaluate the effect of drugs on hiPSC-CMs contractility. A multinational consortium was established with the University of Nottingham as the academic lead, in order to address the CRACK-IT InPulse Challenge. The Challenge consisted of two phases that lasted for 3.5 years.
This project was part of the consortium aimed to develop medium throughput technology platform that could measure contractility in hiPSC-CMs as a physiologically-relevant functional output for use in preclinical drug safety evaluation. The University of Nottingham utilised CellOPTIQ® platform, a medium-high throughput screening platform to measure contractility and electrophysiology.
Protocols were unified across all academic partners via a drug training set in phase 1, allowing subsequent blinded multi-centre evaluation of drugs with known positive, negative, or neutral inotropic effects in phase 2. Accuracy ranged from 44% to 85% across the platform-cell configurations. Refinement to test conditions was addressed after blinded testing, which resulted in increased accuracy to 85% for 2D monolayers and 93% for 3D EHT system.
Through this study, hiPSC-CMs cultured in 2D and 3D platform have been shown to considerably have a value in predictive safety pharmacology despite their immaturity status and current technology evolution.
Item Type
ethesis
Thesis Type
PhD
Supervisors
Keywords
Subjects (LC)
Associated Schools / Departments
School of Medicine
eprints ID
60613
UoN Repository URI
Except where otherwise noted, this item's license is described as
File(s)![Thumbnail Image]()
Name
Thesis_Puspita Anggraini Katili_4255054_FINAL.pdf
Type
Full-text
Description
Examined
Size
17.99 MB
Format
Adobe PDF
Checksum (MD5)
e2bf63fd4bbf5a522b7460db7db2ddca